Publications by authors named "Yasaman Iranmanesh"

Background: Postoperative spinal epidural hematoma (POSEH) causes rapid neurological deficits within 24 h following the operation and can be fatal. However, some POSEH symptoms manifest three days after the operation, also known as delayed POSEH (DPOSEH). Little attention has been provided upon DPOSEH owing to its rare incidence, resulting in serious consequences upon occurrence.

View Article and Find Full Text PDF

Pediatric diffuse gliomas (pDGs) are relatively rare and molecularly distinct from pediatric pilocytic astrocytoma and adult DGs. Immunotherapy is a promising therapeutic strategy, requiring a deep understanding of tumor immune profiles. The spatial locations of brain tumors might be related to the molecular profiles.

View Article and Find Full Text PDF
Article Synopsis
  • Glioblastoma (GBM) is a highly aggressive brain cancer with high recurrence rates due to inadequate responses to traditional treatments and the presence of glioblastoma stem cells (GSCs) that contribute to therapeutic resistance.
  • GSCs exhibit unique characteristics, such as self-renewal and diverse subpopulations, making them distinct from normal neural stem cells and differentiated tumor cells.
  • Understanding the role of mitochondria in GSC metabolism and stress response mechanisms is crucial for developing novel therapies aimed at targeting these resilient cancer cells.
View Article and Find Full Text PDF

Osteoarthritis (OA) is a degenerative joint disease. Currently, apart from symptomatic treatment or joint replacement, no other effective treatments for OA exist. The mechanisms underlying OA remain elusive and require further research.

View Article and Find Full Text PDF

Meningiomas presented preferred intracranial distribution, which may reflect potential biological natures. This study aimed to analyze the preferred locations of meningioma according to different biological characteristics. A total of 1,107 patients pathologically diagnosed with meningiomas between January 2012 and December 2016 were retrospectively analyzed.

View Article and Find Full Text PDF

A major obstacle for treatment of HCC is the inadequate efficacy and limitation of the available therapeutic options. Despite the recent advances in developing novel treatment options, HCC still remains one of the major causes of cancer morbidity and mortality around the world. Achieving effective treatment and eradication of HCC is a challenging task, however recent studies have shown that targeting Natural Killer cells, as major regulators of immune system, can help with the complete treatment of HCC, restoration of normal liver function and subsequently higher survival rate of HCC patients.

View Article and Find Full Text PDF